Highbridge Capital Management

About

Portfolio · 2

BiolineRx

Oncology Therapeutic Pharmaceutical Candidates

Led ★ 1 round $9.0M committed Latest: 2024-11

Gamida Cell

Cellular and Immune Therapies

1 round $30.0M committed Latest: 2024-05

Investment activity

Q&A

What is Highbridge Capital Management's primary sector focus for investments?

Highbridge Capital Management primarily focuses on the Health Tech & Life Sciences sector, with two portfolio companies in this area.

Can you name some of Highbridge Capital Management's portfolio companies?

Highbridge Capital Management's portfolio includes BiolineRx, which focuses on oncology therapeutic pharmaceutical candidates, and Gamida Cell, which develops cellular and immune therapies.

What types of funding stages has Highbridge Capital Management participated in recently?

Highbridge Capital Management has participated in Debt Financing and PIPE rounds, with one investment in each stage.

When did Highbridge Capital Management make its most recent investments?

Highbridge Capital Management made investments in May 2024 and November 2024.

What is the typical investment range for Highbridge Capital Management?

Highbridge Capital Management typically invests between $9M and $30M.

Has Highbridge Capital Management had any exits from its portfolio companies?

According to startupim data, Gamida Cell, a portfolio company of Highbridge Capital Management, has been acquired.